当前位置： SCI文献检索 > JOURNAL OF THROMBOSIS AND THROMBOLYSIS期刊下所有文献 > Awareness and management of pulmonary embolism among physicians in China: a nationwide cross-sectional study.

Awareness and management of pulmonary embolism among physicians in China: a nationwide cross-sectional study.

Abstract：

:Pulmonary embolism (PE) is a leading cause of cardiovascular mortality. We intended to evaluate the awareness and management status of PE among Chinese physicians and provide the basis for establishing Chinese clinical guidelines on PE. We designed a nationwide survey to collect data on physicians' awareness of diagnosis, treatment and follow-up on PE. The questionnaires were distributed to physicians during offline academic meetings and by the online platforms from August 2016 to October 2016. Also, results were sub-grouped by age, hospital grades, departments and trained or not. A total of 2954 valid questionnaires were collected. We observed that there were several defects in the management of PE among Chinese physicians. First, a considerable proportion of physicians chose the incorrect clinical prediction rules for acute PE. Second, a considerable percentage of hospitals could not carry out computed tomographic pulmonary angiography (22.4%) or ventilation-perfusion scintigraphy (65.2%). Third, only a few physicians knew the use of new oral anticoagulants clearly (33.4%). Fourth, only 49% of physicians achieved follow-up management in over half of their patients. Additionally, physicians in the tertiary hospitals, aged > 35 years, trained and from respiratory department have a better knowledge of the management of PE. In conclusion, our survey demonstrates the enhancement of PE-related trainings, especially for physicians in lower-level hospitals, aged ≤ 35 years and from non-respiratory department, can help to improve the management of PE in Chinese physicians. And our study also highlights the need for the establishment of national guidelines for the management of PE in China.

journal_name

J Thromb Thrombolysis

journal_title

Journal of thrombosis and thrombolysis

authors

Zhang M,Zhang YX,Zhang Z,Wang J,Shao X,Xie WM,Wan J,Zhai ZG,Wang C

doi

10.1007/s11239-018-1788-x

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

436-443

issue

3

eissn

0929-5305

issn

1573-742X

pii

10.1007/s11239-018-1788-x

journal_volume

47

pub_type

杂志文章

相关文献

JOURNAL OF THROMBOSIS AND THROMBOLYSIS文献大全
  • Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis.

    abstract：:The Tissue Factor/Factor VIIa (TF/FVIIa) complex is an attractive target for pharmacological interruption of thrombin generation and hence blood coagulation, as this complex is the initiation point of the extrinsic pathway of coagulation. TF is a cell membrane-associated protein that interacts with soluble FVIIa to ac...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/a:1023228827733

    authors： Szalony JA,Taite BB,Girard TJ,Nicholson NS,LaChance RM

    更新日期：2002-10-01 00:00:00

  • Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia.

    abstract：:Heparin induced thrombocytopenia (HIT) is a life and limb-threatening complication of heparin exposure. The misdiagnosis of this disease can have major consequences on the patients. The objective of this study was to evaluate a diagnostic strategy that combines the 4Ts score with the result of HemosIL® AcuStar HIT-IgG...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02349-4

    authors： Marashi-Sabouni Z,Vayne C,Ibrahim-Kosta M,Guidon C,Loundou A,Guery EA,Morange PE,Camoin-Jau L

    更新日期：2021-01-01 00:00:00

  • Persisting autoimmune heparin-induced thrombocytopenia after elective abdominal aortic aneurysm repair: a case report.

    abstract：:Persisting heparin-induced thrombocytopenia (HIT) is characterized by ongoing thrombocytopenia more than 7 days after stopping heparin. It is part of cases referred to as autoimmune HIT (aHIT). In contrast to typical HIT cases, aHIT involves heparin-independent platelet activation mechanism highlighted by a strongly p...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02062-2

    authors： Roberge G,Tritschler T,MacGillivray C,Dufresne L,Nagpal SK,Scarvelis D

    更新日期：2020-10-01 00:00:00

  • The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

    abstract：:The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous active control agent, anivamersen. Its effect on thrombin generation is unknown. A prospectively designed thrombin generation study was conducted within the phase 1 ascending dose s...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s11239-014-1081-6

    authors： Vavalle JP,Rusconi CP,Zelenkofske S,Wargin WA,Ortel TL,Alexander JH,Povsic TJ,Becker RC

    更新日期：2014-10-01 00:00:00

  • Thromboembolic complications in inflammatory bowel disease.

    abstract：:Patients with inflammatory bowel disease (IBD) have a 1.5-3.5-fold higher risk of thromboembolism when compared to the non-IBD population and the risk is much more prominent at the time of a flare. Arterial thromboembolism (ischemic stroke, focal white matter ischemia, cardiac ischemia, peripheral vascular disease and...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-014-1129-7

    authors： Kohoutova D,Moravkova P,Kruzliak P,Bures J

    更新日期：2015-05-01 00:00:00

  • Risk factors for intracerebral hemorrhage in patients with COVID-19.

    abstract：:Intracerebral hemorrhage (ICH) can be a devastating complication of coronavirus disease (COVID-19). We aimed to assess risk factors associated with ICH in this population. We performed a retrospective cohort study of adult patients admitted to NYU Langone Health system between March 1 and April 27 2020 with a positive...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02288-0

    authors： Melmed KR,Cao M,Dogra S,Zhang R,Yaghi S,Lewis A,Jain R,Bilaloglu S,Chen J,Czeisler BM,Raz E,Lord A,Berger JS,Frontera JA

    更新日期：2020-09-24 00:00:00

  • 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.

    abstract：BACKGROUND AND OBJECTIVE:The 4G/5G plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism has been associated with basal PAI-1 levels, with ischemic heart disease, and with adverse prognosis in critically ill patients. We hypothesized it might also influence the acute-phase levels of PAI-1 following coronary b...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/B:THRO.0000024052.79415.62

    authors： Burzotta F,Iacoviello L,Di Castelnuovo A,Zamparelli R,D'Orazio A,Amore C,Schiavello R,Donati MB,Maseri A,Possati G,Andreotti F

    更新日期：2003-12-01 00:00:00

  • Secondary prevention strategies for coronary heart disease.

    abstract：:Patients with established coronary heart disease (CHD) have a high risk of subsequent cardiovascular events, including myocardial infarction (MI), stroke, and death from cardiovascular disease. Adherence to evidence-based secondary prevention therapies for CHD has improved in recent years but still remains suboptimal....

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-009-0381-8

    authors： Weiner SD,Rabbani LE

    更新日期：2010-01-01 00:00:00

  • The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa.

    abstract：:The anticoagulant properties of a novel RNA aptamer that binds FIXa depend collectively on the intensity of surface contact activation of human blood plasma, aptamer concentration, and its binding affinity for FIXa. Accordingly, anticoagulation efficiency of plasma containing any particular aptamer concentration is lo...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-012-0778-7

    authors： Krishnan A,Vogler EA,Sullenger BA,Becker RC

    更新日期：2013-01-01 00:00:00

  • Challenges and benefits of an inpatient anticoagulation service: one hospital's experience.

    abstract：:While outpatient anticoagulation services (AMS) have existed extensively for a number of years, inpatient AMS have only recently begun to be implemented on a widespread basis. This is in direct response to anticoagulation regulations set forth by entities such as the Joint Commission (TJC) and the Centers for Medicare...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-011-0563-z

    authors： Burnett A,D'Angio R,Earl LE,Garcia D

    更新日期：2011-04-01 00:00:00

  • Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice.

    abstract：BACKGROUND:The role of alpha2-antiplasmin (alpha2-AP) on platelet aggregation was investigated using mice deficient in alpha2-AP (alpha2-AP(-/-)) or using wild type mice (alpha2-AP(+/+)). METHODS:Blood samples were taken from each mouse under anesthesia with ether and platelet rich plasma (PRP) was prepared. Platelet ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/a:1025096609558

    authors： Takei M,Matsuno H,Okada K,Ueshima S,Matsuo O,Kozawa O

    更新日期：2002-12-01 00:00:00

  • Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.

    abstract：:Anticoagulant plasma concentrations and patient characteristics might affect the benefit-risk balance of therapy. The study objective was to assess the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes in patients receiving rivaroxaban for venous thromboembolism (VTE) prophylaxis (...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02078-8

    authors： Reinecke I,Solms A,Willmann S,Spiro TE,Peters G,Weitz JI,Mueck W,Garmann D,Schmidt S,Zhang L,Fox KAA,Berkowitz SD

    更新日期：2020-07-01 00:00:00

  • Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations.

    abstract：:The American College of Chest Physicians (ACCP) has established guidelines for the treatment of VTE, but the generalizability to all populations is unclear. In this review we analyzed the rate of reporting and enrollment of blacks and women in clinical trials cited in the ACCP guidelines for treatment of unprovoked VT...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-016-1352-5

    authors： Sullivan LT 2nd,Jackson LR 2nd,Thomas KL

    更新日期：2016-08-01 00:00:00

  • Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study.

    abstract：:The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism [VTE] is still unclear. To evaluate the presence of the F2 polymorphism in VTE patients compared to healthy blood donors and to adjust the results for common inherited thro...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02169-6

    authors： Limperger V,Kenet G,Kiesau B,Köther M,Schmeiser M,Langer F,Juhl D,Shneyder M,Franke A,Klostermeier UK,Mesters R,Rühle F,Stoll M,Steppat D,Kowalski D,Rocke A,Kuta P,Bajorat T,Torge A,Neuner B,Junker R,Nowak-Göttl

    更新日期：2020-06-27 00:00:00

  • Low levels of activated factor VII in systemic sclerosis.

    abstract：INTRODUCTION:Recent investigations show that activated factor VII, the primary enzyme in the extrinsic pathway of blood coagulation, exerts additional extra-coagulant functions, such as apoptosis and angiogenesis. On the basis of these recent acquisitions, the present study was aimed to evaluate activated factor VII in...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-006-8969-8

    authors： Volpe A,Salvagno GL,Lippi G,Caramaschi P,Montagnana M,Canestrini S,Carletto A,Bambara LM,Biasi D,Guidi GC

    更新日期：2006-10-01 00:00:00

  • Acute Myocardial Infarction in Canada: New Epidemiologic Insights on Incidence, Therapy, and Risk.

    abstract：:Objective: To define the changing incidence, risk, and therapy of acute myocardial infarction (A311). Data sources: Review of contemporary AMI data from the University of Alberta Hospitals, six other sites of the Clinical Quality Improvement Network (CQIN), and other Canadian and international centers. Data synthesis:...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF00132402

    authors： Montague T,Montague P,Barnes M,Taylor L,Wowk L,Fassbender K,Ackman M,Martin S,Armstrong PW,Teo K

    更新日期：1996-01-01 00:00:00

  • Effect of Poloxamer 188 on Collateral Blood Flow, Myocardial Infarct Size, and Left Ventricular Function in a Canine Model of Prolonged (3-Hour) Coronary Occlusion and Reperfusion.

    abstract：:Poloxamer 188 is a surfactant with hemorheological, antithrombotic, and neutrophil-inhibitory properties. This agent has been demonstrated to reduce infarct size and to improve left ventricular function in animal models of myocardial infarction and reperfusion, and recently in a randomized trial of patients receiving ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/A:1008848026759

    authors： Kelly RF,Hursey TL,Patel RB,Parrillo JE,Schaer GL

    更新日期：1998-07-01 00:00:00

  • Venous thromboembolism: patient awareness and education in the pre-operative assessment clinic.

    abstract：:Each year venous thromboembolism (VTE) causes up to 60,000 deaths in the UK, many resulting from hospital-acquired thromboses following elective surgery. National Institute for Health and Clinical Excellence (NICE) guidelines state that all elective surgical patients should receive verbal and written information pre-o...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-015-1224-4

    authors： Haymes A

    更新日期：2016-04-01 00:00:00

  • PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count.

    abstract：:Peripherally inserted central catheters (PICCs) for central venous access are frequently used in patients with hematological malignancies. Their use may be complicated by upper extremity deep venous thrombosis (UEDVT). Additionally, hematological patients are frequently thrombocytopenic and the optimal management of U...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02040-8

    authors： Scamuffa MC,Morano SG,Serrao A,Bruzzese A,Stocchi F,Santoro C,Vozella F,Latagliata R,Chistolini A

    更新日期：2020-04-01 00:00:00

  • Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype.

    abstract：:Sickle cell disease (SCD) is characterised by abnormal coagulopathy and angiogenesis although their relationships in two common genotypes, homozygous (HbSS) SCD and sickle-haemoglobin C disease (HbSC), are unexplored. We measured markers of platelet activation (soluble P-selectin [sP-selectin]), fibrinolysis (D-dimer)...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-007-0177-7

    authors： Blann AD,Mohan JS,Bareford D,Lip GY

    更新日期：2008-04-01 00:00:00

  • Possible mechanisms of aspirin resistance.

    abstract：:Data regarding possible mechanisms of aspirin (ASA) resistance in patients with recurrent myocardial infarction (MI) or vascular ischemia are limited. Five major possible mechanisms of ASA resistance are documented in the primary literature and are discussed in this paper. These mechanisms include: (1) inadequate bloc...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1023/a:1015324310374

    authors： Cambria-Kiely JA,Gandhi PJ

    更新日期：2002-02-01 00:00:00

  • Description of anti-Xa monitoring practices during low molecular weight heparin use.

    abstract：:Certain patient populations (pregnancy, cancer, renal impairment, and obesity) may be at higher risk of adverse events during low molecular weight heparin (LMWH) therapy and may benefit from anti-Xa monitoring. Yet, evidence supporting a standardized approach to anti-Xa monitoring correlated to clinical outcomes is la...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-01920-y

    authors： Lin A,Vazquez SR,Jones AE,Witt DM

    更新日期：2019-11-01 00:00:00

  • Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group.

    abstract：:It has been reported that platelet expression and plasma levels of soluble P-selectin are increased in patients with unstable coronary artery syndromes. However, the origin of soluble P-selectin remains unknown. We sought to determine whether platelet expression of P-selectin correlates with plasma levels in the popul...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1018738502654

    authors： Gurbel PA,Kereiakes DJ,Serebruany VL

    更新日期：2000-08-01 00:00:00

  • The ADP receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia.

    abstract：BACKGROUND:The endothelial ADP receptor P2Y(1) is responsible for a large part of the reactive hyperemia following cardiac ischemia. Tissue plasminogen activator (t-PA) increases during reactive hyperemia. We postulated that the release of t-PA during reactive hyperemia could be mitigated through blocking the coronary ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-007-0010-3

    authors： Olivecrona GK,Götberg M,Harnek J,Jacobson KA,Jern S,Erlinge D

    更新日期：2007-10-01 00:00:00

  • Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis.

    abstract：:No study investigated the possible detrimental effect of stress hyperglycemia on patients affected acute ischemic stroke (AIS) undergoing intravenous thrombolysis (IVT). A new index, the glucose-to-glycated hemoglobin ratio (GAR), has been developed for assessing stress hyperglycemia. We retrospectively analyzed data ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02252-y

    authors： Merlino G,Smeralda C,Gigli GL,Lorenzut S,Pez S,Surcinelli A,Marini A,Valente M

    更新日期：2020-08-24 00:00:00

  • The pharmacology of novel oral anticoagulants.

    abstract：:Anticoagulation for the prevention of stroke is an important aspect of the management of atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran have emerged as important therapeutic treatment options for prevention of stroke i...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-013-0967-z

    authors： DeWald TA,Becker RC

    更新日期：2014-01-01 00:00:00

  • Bleeding risk factors associated with argatroban therapy in the critically ill.

    abstract：:Argatroban is a parenteral direct thrombin inhibitor labeled for anticoagulation in patients with confirmed or suspected heparin-induced thrombocytopenia in the United States. Currently there are no studies evaluating bleeding risk factors in Intensive Care Unit patients.To determine bleeding risk factors associated w...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-012-0758-y

    authors： Doepker B,Mount KL,Ryder LJ,Gerlach AT,Murphy CV,Philips GS

    更新日期：2012-11-01 00:00:00

  • Screening for paroxysmal nocturnal hemoglobinuria (PNH) in patients presenting with cerebral sinovenous thrombosis (CSVT): Results of a FLAER based flowcytometry study in Indian patients.

    abstract：:Patients with paroxysmal nocturnal hemoglobinuria (PNH) may present with thrombosis at unusual sites, of which cerebral sinovenous thrombosis (CSVT) is one and screening for PNH is recommended in this condition. Though many patients diagnosed with PNH develop CSVT, it is unclear how many patients with PNH would presen...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-01982-y

    authors： Sharma S,Ahluwalia J,Atreja CB,Modi M,Sachdeva MS,Kumar N,Bose P,Bose SK,Uppal V,Lal V,Varma N

    更新日期：2020-05-01 00:00:00

  • Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect.

    abstract：:The purpose of the currents study was to enhance bioavailability of rivaroxaban (RXB) and reduce the food effect. RXB loaded PLGA nanoparticles (RXB-PLGA-NPs) were prepared by emulsion solvent evaporation method and optimized using central composite design (CDD). The optimized RXB-PLGA-NPs (F8) with composition, PLGA ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-02022-5

    authors： Anwer MK,Mohammad M,Iqbal M,Ansari MN,Ezzeldin E,Fatima F,Alshahrani SM,Aldawsari MF,Alalaiwe A,Alzahrani AA,Aldayel AM

    更新日期：2020-04-01 00:00:00

  • EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy.

    abstract：:Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single dose of EPO (60,000 U) in patients with ST-segment elevation myocardial infarction. In a substudy, we aimed to determi...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11239-013-0944-6

    authors： Povsic TJ,Najjar SS,Prather K,Zhou J,Adams SD,Zavodni KL,Kelly F,Melton LG,Hasselblad V,Heitner JF,Raman SV,Barsness GW,Patel MR,Kim RJ,Lakatta EG,Harrington RA,Rao SV

    更新日期：2013-11-01 00:00:00